论文部分内容阅读
目的 检测肝癌及癌旁组织中缺氧诱导因子-1 α(HIF-1 α)基因蛋白的表达及临床意义。方法 用免疫组织化学、western blot和RT—PCR技术检测35例肝细胞癌、26例肝硬化组织及15例正常肝组织中HIF-1 α蛋白和基因的表达情况,并分析其与临床病理特点之间的关系。 结果 免疫组织化学显示HIF-1α蛋白在肝硬化和肝癌组织中普遍表达,在肝硬化组织中的表达明显高于正常肝脏组织中的表达;但肝癌组织中因大片状坏死后伴大量纤维结缔组织增生的肝细胞条索中HIF-1 α蛋白的表达强度高于肝硬化组织,肝硬化组织HIF-1α蛋白的表达强度明显高于肝癌组织(54％与31％,x2=4.09,P<0.05);westernblot和RT-PCR结果与免疫组化结果相似。HIF-1α蛋白在肝癌组织中的表达强度与分化程度有关(x2=4.64,P<0.05),与有无肝内外转移有关(x2=7.15,P<0.05);但HIF-1α的表达与门静脉有无癌栓、预后及HBsAg表达无关。 结论 HIF-1 α蛋白在肝癌和肝硬化组织中普遍表达,且只受缺氧因素的影响,与肿瘤的分化程度和肝癌的转移有关,但与有无门静脉癌栓、HBsAg表达及预后无关,为肝癌的治疗提供新的思路。
Objective To detect the expression of hypoxia inducible factor-1α (HIF-1α) gene in hepatocellular carcinoma and its adjacent tissues and its clinical significance. Methods Immunohistochemistry, western blot and RT-PCR were used to detect the protein and gene expression of HIF-1α in 35 cases of hepatocellular carcinoma, 26 cases of cirrhosis and 15 cases of normal liver tissues. The expressions of HIF- The relationship between. Results Immunohistochemistry showed that HIF-1αprotein was universally expressed in cirrhosis and hepatocellular carcinoma, and was significantly higher in cirrhosis than in normal liver tissue. However, in HCC there was a large number of fibrous connective tissue The expression of HIF-1α protein in hepatocellular cord was higher than that in cirrhotic tissue. The expression of HIF-1α protein in cirrhosis was significantly higher than that in HCC (54% vs 31%, x2 = 4.09, P < 0.05). Westernblot and RT-PCR results were similar to those of immunohistochemistry. The expression of HIF-1α in hepatocellular carcinoma was correlated with the degree of differentiation (x2 = 4.64, P <0.05), with or without extrahepatic metastasis (x2 = 7.15, P <0.05) Whether tumor thrombus, prognosis and HBsAg expression has nothing to do. Conclusions HIF-1α protein is universally expressed in hepatocellular carcinoma and cirrhosis tissues and is only affected by hypoxia, which is related to the degree of tumor differentiation and metastasis of HCC. However, HIF-1α protein has no correlation with the presence or absence of portal vein tumor thrombus and HBsAg expression, Provide a new way for the treatment of liver cancer.